• 1
    Parkin DM, Pisani P, Ferlay J. Global cancer statistics. CA Cancer J Clin. 1999; 49: 3364.
  • 2
    Vaidya A, Soloway MS, Hawke C, et al. De novo muscle invasive bladder cancer: is there a change in trend? J Urol. 2001; 165: 4750.
  • 3
    Stein JP, Grossfeld GD, Freeman JA, et al. Orthotopic lower urinary tract reconstruction in women using the Kock ileal neobladder: updated experience in 34 patients. J Urol. 1997; 158: 400405.
  • 4
    Elmajian DA, Stein JP, Esrig D, et al. The Kock ileal neobladder: updated experience in 295 male patients. J Urol. 1996; 156: 920925.
  • 5
    Stein JP, Lieskovsky G, Cote R, et al. Radical cystectomy in the treatment of invasive bladder cancer: long term results in 1054 patients. J Clin Oncol. 2001; 19: 666675.
  • 6
    Ghoneim MA, el-Mekresh MM, el-Baz MA, et al. Radical cystectomy for carcinoma of the bladder: critical evaluation of the results in 1026 cases. J Urol. 1997; 158: 393399.
  • 7
    Madersbacher S, Hochreiter W, Burkhard F, et al. Radical cystectomy for bladder cancer today—a homogeneous series without neoadjuvant chemotherapy. J Clin Oncol. 2003; 21: 690696.
  • 8
    Vale C, for the Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Neoadjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis. Lancet. 2003; 361: 19271934.
  • 9
    Winquist E, Kirchner TS, Segal R, et al. Neoadjuvant chemotherapy for transitional cell carcinoma of the bladder. A systematic review and meta-analysis. J Urol. 2004; 171: 561569.
  • 10
    Logothethis CJ, Johnson DE, Chong C, et al. Adjuvant cyclophosphamide, doxorubicin and cisplatin chemotherapy for bladder cancer. An update. J Clin Oncol. 1988; 6: 15901596.
  • 11
    Skinner DG, Daniels JR, Russell CA, et al. The role of adjuvant chemotherapy following cystectomy for invasive bladder cancer: a prospective comparative trial. J Urol. 1991; 145: 459467.
  • 12
    Stockle M, Meyenburg W, Wellek S, et al. Advanced bladder cancer (stages pT3b, pT4a, pN1 and pN2): improved survival after radical cystectomy and 3 adjuvant cycles of chemotherapy. Results of a controlled prospective study. J Urol. 1992; 148: 302307.
  • 13
    Studer UE, Bacchi M, Biedermann C, et al. Adjuvant cisplatin chemotherapy following cystectomy for bladder cancer: a prospective randomized trial. J Urol. 1994; 152: 8184.
  • 14
    Freiha F, Reese J, Torti FM. A randomised trial of radical cystectomy versus radical cystectomy plus cisplatin, vinblastine and methotrexate chemotherapy for muscle invasive bladder cancer. J Urol. 1996; 155: 495500.
  • 15
    Bono AV, Benvenuti C, Reali L, et al. Adjuvant chemotherapy in advanced bladder cancer. Prog Clin Biol Res. 1989; 303: 533540.
  • 16
    Sylvester R, Sternberg C. The role of adjuvant combination chemotherapy after cystectomy in locally advanced bladder cancer: what we do not know and why. Ann Oncol. 2000; 11: 851856.
  • 17
    National Cancer Institute. Levels of evidence for adult cancer treatment studies, health professional version (date last modified: 6/6/ 2003). Available at URL: [accessed December 31, 2004].
  • 18
    Pignon JP, Hill C. Meta-analyses of randomized clinical trials in oncology. Lancet Oncol. 2001; 2: 475482.
  • 19
    Bria E, Giannarelli D, Felici A, et al. Taxanes with anthracyclines as first-line chemotherapy for metastatic breast carcinoma. Cancer. 2005; 103: 672679; Jan 6 [Epub ahead of print].
  • 20
    Parmar MKB, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med. 1998; 17: 28152834.
  • 21
    Douglas Case L, Kimmick G, Paskett ED, et al. Interpreting measures of treatment effect in cancer clinical trials. Oncologist. 2002; 7: 181187.
  • 22
    Parmar MKB, Machin D. Survival analysis: a practical approach. Chichester, UK: John Wiley & Sons, 1995.
  • 23
    Millikan R, Dinney C, Swanson D, et al. Integrated therapy for locally advanced bladder cancer: final report of a randomised trial of cystectomy plus adjuvant M-VAC versus cystectomy with both preoperative and postoperative M-VAC. J Clin Oncol. 2001; 19: 40054013.
  • 24
    Stockle M, Meyenburg W, Wellek S, et al. Adjuvant polychemotherapy of non organ-confined bladder cancer after radical cystectomy revisited: long-term results of a controlled prospective study and further clinical experience. J Urol. 1995; 153: 4752.
  • 25
    Stockle M, Wellek A, Meyenburg W, et al. Radical cystectomy with or without adjuvant polychemotherapy for non organ-confined transitional cell carcinoma of the urinary bladder: prognostic impact of lymphnode involvement. Urology. 1996; 48: 868875.
  • 26
    Bono AV, Benvenuti C, Gibba A, et al. Adjuvant chemotherapy in locally advanced bladder cancer. Final analysis of a controlled multicentre study. Acta Urol Ital. 1997; 11: 58.
  • 27
    Logothetis CJ, Dexeus FH, Finn L, et al. A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors. J Clin Oncol. 1990; 8: 10501055.
  • 28
    Loehrer PJ, Einhorn LH, Elson PJ, et al. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol. 1992; 10: 10661073.
  • 29
    Piedbois P. Meta-analyses based on abstracted data: a step in the right direction, but only a first step. J Clin Oncol. 2004; 9: 38393841.